Bolt Biotherapeutics, Inc.
BOLTHealthcare|Biotechnology|US
$6.54
+0.16 (+2.51%)
Tangible Book / Share
$7.48
Cash / Share
$10.41
Clinical Trials (4)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT06921837 A First-in-Human Study Using BDC-4182 as a Single Agent in Advanced Gastric and Gastroesophageal Cancer | Gastric Cancer Adenocarcinoma Metastatic, Gastroesophageal Adenocarcinoma | P1P2 | Recruiting | 122 | Open-label | BDC-4182 |
| NCT04278144 A First-in-human Study Using BDC-1001 as a Single Agent and in Combination With Nivolumab in Advanced HER2-Expressing Solid Tumors | HER2-positive Solid Tumors, HER2-positive Breast Cancer | P1P2 | Terminated | 175 | Open-label | BDC-1001, Nivolumab |
| NCT05954143 Trial of BDC-1001 +/- Pertuzumab in Subjects With HER2-Positive Metastatic Breast Cancer | Metastatic Breast Cancer, HER2-positive Breast Cancer | P2 | Terminated | 11 | RCT, Open-label | BDC-1001, Pertuzumab |
| NCT06052852 Study of BDC-3042 as Single Agent and in Combination With Cemiplimab in Patients With Advanced Malignancies | Triple Negative Breast Cancer, Clear Cell Renal Cell Carcinoma | P1 | Terminated | 17 | Open-label | BDC-3042, Cemiplimab |